US Influenza Vaccine Market to Exceed USD 2.5 Bn by 2022, Forecasts DPI Research in Its New Report Available at MarketPublishers.com13 Dec 2016 • by Natalie Aster
LONDON – The influenza vaccine marketplace in the USA is projected to surpass a value of USD 2.5 billion by 2022.
The market is poised to gain traction owing to factors like higher awareness of the disease, extended recommendations by government and advisory agencies for seasonal influenza vaccination, a hike in the number of the elderly people in the majority of countries, as well as the introduction of quadrivalent (IIV4) influenza vaccine.
Meantime, amid the barriers restraining the influenza sector growth and entrance of new players one can name lack of awareness amid patients regarding the threat of influenza and the significance of influenza vaccinations, intensive investment and stiff regulations.
Sanofi Pasteur, Seqirus, GSK, Protein Sciences Corporation and AstraZenecca are the key influencers with their products taking the lead in the seasonal influenza vaccine marketplace. Other emerging players like Novavax, Mitsubishi Tanabe Pharma, Daiichi–Sankyo, VaxInnate and BiondVax Pharmaceuticals Ltd are manufacturing new technology based influenza vaccine which is poised to impact the market share in the years to come.
New research study “United States Influenza Vaccine Market” elaborated by DPI Research & Marketing Solutions presents an all-round analysis and forecast of the market on a country level.
The study gives details about the patterns of vaccination, dose distributions, production alongside offers a granular view of the regulatory scenario. The report offers insights into clinical trials, pipeline and high-potential vaccines in the domestic market for influenza vaccines. It keeps track of the major trends related to M&A, licensing agreements and collaborations. The report contains profiles of the top players engaged in the influenza vaccine sector. The leading market players are examined based on various parameters like business overview, product portfolio outlook and sales analysis of influenza vaccine sector during 2011-2022. Other emerging players are carefully reviewed as well. The research report also sheds light on the main drivers of, and barriers to the growth of the country’s influenza vaccine market.
Many other new reports by this publisher are gives at the DPI Research & Marketing Solutions page.